Erin Bussin1, Brian Cairns2, Tommy Gerschman3, Michael Fredericson4, Jim Bovard5, Alex Scott6. 1. Fortius Sports Medicine, Burnaby, British Columbia, Canada. 2. Faculty of Pharmaceutical Sciences, University of British Columbia, Vancouver, Canada. 3. Department of Pediatrics, University of British Colombia, Vancouver, Canada. 4. Department of Orthpaedic Surgery, Stanford University, Stanford, California, United States of America. 5. Department of Family Practice, University of British Columbia, Vancouver, Canada. 6. Department of Physical Therapy, University of British Columbia, Vancouver, Canada.
Abstract
INTRODUCTION: The application of topical diclofenac has been suggested as a possible treatment for Achilles tendinopathy. Our aim was to answer the question, is topical diclofenac more effective than placebo for the treatment of Achilles tendinopathy?. METHODS:67 participants with persistent midportion or insertional Achilles tendinopathy were randomly assigned to receive a 4 week course of 10% topical diclofenac (n = 32) or placebo (n = 35). The a priori primary outcome measure was change in severity of Achilles tendinopathy (VISA-A score) at 4 and 12 weeks. Secondary outcome measures included numeric pain rating, and patient-reported change in symptoms using a 7 point scale, from substantially worse to substantially better. Pressure pain threshold (N) and transverse tendon stiffness (N/m) were measured over the site of maximum Achilles tendon pathology at baseline and 4 weeks. RESULTS: There were no statistically or clinically significant differences between the diclofenac and placebo groups in any of the primary or secondary outcome measures at any timepoint. Average VISA-A score improved in both groups (p<0.0001), but the improvements were marginal: at 4 weeks, the improvements in VISA-A were 9 (SD 11) in the diclofenac group and 8 (SD 12) in the placebo group, and at 12 weeks the improvements were 9 (SD 16) and 11 (SD13) respectively-these average changes are smaller than the minimum clinically important difference of the VISA-A. CONCLUSION: The regular application of topical diclofenac for Achilles tendinopathy over a 4 week period was not associated with superior clinical outcomes to that achieved with placebo.
RCT Entities:
INTRODUCTION: The application of topical diclofenac has been suggested as a possible treatment for Achilles tendinopathy. Our aim was to answer the question, is topical diclofenac more effective than placebo for the treatment of Achilles tendinopathy?. METHODS: 67 participants with persistent midportion or insertional Achilles tendinopathy were randomly assigned to receive a 4 week course of 10% topical diclofenac (n = 32) or placebo (n = 35). The a priori primary outcome measure was change in severity of Achilles tendinopathy (VISA-A score) at 4 and 12 weeks. Secondary outcome measures included numeric pain rating, and patient-reported change in symptoms using a 7 point scale, from substantially worse to substantially better. Pressure pain threshold (N) and transverse tendon stiffness (N/m) were measured over the site of maximum Achilles tendon pathology at baseline and 4 weeks. RESULTS: There were no statistically or clinically significant differences between the diclofenac and placebo groups in any of the primary or secondary outcome measures at any timepoint. Average VISA-A score improved in both groups (p<0.0001), but the improvements were marginal: at 4 weeks, the improvements in VISA-A were 9 (SD 11) in the diclofenac group and 8 (SD 12) in the placebo group, and at 12 weeks the improvements were 9 (SD 16) and 11 (SD13) respectively-these average changes are smaller than the minimum clinically important difference of the VISA-A. CONCLUSION: The regular application of topical diclofenac for Achilles tendinopathy over a 4 week period was not associated with superior clinical outcomes to that achieved with placebo.
Authors: Anders P Boesen; Henning Langberg; Rudi Hansen; Peter Malliaras; Morten I Boesen Journal: Scand J Med Sci Sports Date: 2019-05-29 Impact factor: 4.221
Authors: Peter H T Tran; Nikolaj M Malmgaard-Clausen; Rikke S Puggaard; René B Svensson; Janus D Nybing; Philip Hansen; Peter Schjerling; Amanda H Zinglersen; Christian Couppé; Mikael Boesen; S Peter Magnusson; Michael Kjaer Journal: FASEB J Date: 2019-11-26 Impact factor: 5.191
Authors: J M Robinson; J L Cook; C Purdam; P J Visentini; J Ross; N Maffulli; J E Taunton; K M Khan Journal: Br J Sports Med Date: 2001-10 Impact factor: 13.800
Authors: Alex Scott; Sean Docking; Bill Vicenzino; Håkan Alfredson; Richard J Murphy; Andrew J Carr; Johannes Zwerver; Kirsten Lundgreen; Oliver Finlay; Noel Pollock; Jill L Cook; Angela Fearon; Craig R Purdam; Alison Hoens; Jonathan D Rees; Thomas J Goetz; Patrik Danielson Journal: Br J Sports Med Date: 2013-04-12 Impact factor: 13.800